Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01635283 · ClinicalTrials.gov registry record · Phase 2
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01635283: Completed Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT01635283 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01635283, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients. Other goals of this study are to determine if the vaccine can cause an immune response against patients' cancer cells and slow the growth of their brain tumors
Primary Outcome
a Kaplan-Meier curve of the PFS of our trial patients was created and compared to the PFS of control patients matched for tumor grade, recurrence number, IDH1 status and 1p/19q status.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL tumor lysate-pulsed autologous dendritic cell vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-01-10 |
| Est. Completion | 2016-05-13 |
| Phase | Phase 2 |
What the finished NCT01635283 record still lists
NCT01635283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01635283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01635283 about?
NCT01635283 is a clinical study titled "Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma". The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients. Other goals of this study are to determine if the vaccine can cause an immune...
What is the current status of trial NCT01635283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2012-01-10. Estimated completion is 2016-05-13.
What interventions are being tested in trial NCT01635283?
The interventions under investigation include: laboratory biomarker analysis (OTHER), tumor lysate-pulsed autologous dendritic cell vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01635283?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01635283's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI